Regeneron Reports Third Quarter 2020 Financial and Operating Results
The Pharma Data
NOVEMBER 5, 2020
Business Highlights. Key Pipeline Progress Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. Updates from the clinical pipeline include: Dupixent ® (dupilumab). Corporate and Business Development Update.
52 
Let's personalize your content